The cancer cell with this resistance can sustain oncogenic signaling with continuous inhibition of target molecules, such as EGFR and HER2 amplification upon MET exon 14 inhibition in non-small lung cancer (NSCLC) [19,20]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.